Cirio acted as legal advisor to AstraZeneca in its sale of US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi) against an upfront consideration of $1.5bn, consisting of $1.0bn in cash and $500m in ordinary shares of Sobi upon completion.
Cirio’s team consisted mainly of Carl-Olof Bouveng, Maria Arnoldsson and Jessika Lagebro.
Fore more information, please contact:
